TTC21B

Chr 2ADAR

tetratricopeptide repeat domain 21B

Also known as: ATD4, CFAP60, FAP60, FLA17, IFT139, IFT139B, JBTS11, NPHP12

This gene encodes a member of TTC21 family, containing several tetratricopeptide repeat (TPR) domains. This protein is localized to the cilium axoneme, and may play a role in retrograde intraflagellar transport in cilia. Mutations in this gene are associated with various ciliopathies, nephronophthisis 12, and asphyxiating thoracic dystrophy 4. [provided by RefSeq, Oct 2011]

Primary Disease Associations & Inheritance

Nephronophthisis 12MIM #613820
ADAR
Short-rib thoracic dysplasia 4 with or without polydactylyMIM #613819
AR
UniProtJoubert syndrome 11
177
ClinVar variants
23
Pathogenic / LP
0.00
pLI score
0
Active trials
Clinical SummaryTTC21B
🧬
Gene-Disease Validity (ClinGen)
nephronophthisis 12 · ARDefinitive

Definitive — sufficient evidence for diagnostic panels

Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
23 Pathogenic / Likely Pathogenic· 88 VUS of 177 total submissions

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint?LOEUF (Loss-of-function Observed/Expected Upper bound Fraction) is the upper bound of the 90% CI for LoF OE — the preferred gnomAD v4 metric. Lower = more intolerant to LoF. LOEUF < 0.35 = highly constrained.
0.85LOEUF
pLI 0.000
Z-score 2.64
OE 0.68 (0.540.85)
Tolerant

Typical tolerance to LoF variation

Missense Constraint?Missense Z-score: standard deviations fewer missense variants observed vs. expected. Z > 3.09 (p < 0.001) = gene does not tolerate missense variation. OE missense < 0.6 is also considered constrained.
-0.41Z-score
OE missense 1.04 (0.981.11)
724 obs / 693.7 exp
Tolerant

Tolerant to missense variation

Observed / Expected Ratios?Shaded band = 90% confidence interval. Vertical tick = point estimate. Grey threshold line = gnomAD constraint cutoff for that variant class.
LoF OE?Ratio of observed to expected LoF variants. Upper CI bound (LOEUF) ≤ 0.35 = strong LoF constraint signal.0.68 (0.540.85)
00.351.4
Missense OE?Ratio of observed to expected missense variants. OE ≤ 0.6 = fewer missense variants than expected by chance.1.04 (0.981.11)
00.61.4
Synonymous OE?Control metric — synonymous variants are largely neutral and expected near OE = 1.0. Significant deviation may indicate annotation issues.1.08
01.21.6
LoF obs/exp: 53 / 78.2Missense obs/exp: 724 / 693.7Syn Z: -0.92

ClinVar Variant Classifications

177 submitted variants in ClinVar

Classification Summary

Pathogenic13
Likely Pathogenic10
VUS88
Likely Benign65
Conflicting1
13
Pathogenic
10
Likely Pathogenic
88
VUS
65
Likely Benign
1
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
5
0
8
0
13
Likely Pathogenic
6
0
4
0
10
VUS
1
81
4
2
88
Likely Benign
0
1
27
37
65
Benign
0
0
0
0
0
Conflicting
1
Total12824339177

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

TTC21B · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

OMIM — Genotype-Phenotype Relationships

1 OMIM entry

Nephronophthisis 12

MIM #613820

Molecular basis of disorder known

Autosomal dominantAutosomal recessive

Short-rib thoracic dysplasia 4 with or without polydactyly

MIM #613819

Molecular basis of disorder known

Autosomal recessive
📖
GeneReview available — TTC21B
Authoritative clinical overview · NCBI Bookshelf · Recommended first read
Open GeneReview ↗
Clinical Literature
Landmark / reviewRecent case evidence
Recent Gene-Specific Literature
Gene in title · MEDLINE · newest first
Europe PMC

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →